CDK9 and cancer: Treatment with the CDK2/9 inhibitor CYC065 (Fadraciclib) having antagonism of CDK2 > CDK9 substantially increased the presence of cancer cells with multipolar mitotic spindles across diverse aneuploid cancer cells (19, 20).